d. Jeffrey Keyser

Executive

Director

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 1 buy · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€85k

▼ Sales (0 ops.)

—

Latest filing published 14 May 2026 for Lantern Pharma Inc., €85k. Read the official filing

Filing timeline

BuySale

d. Jeffrey Keyser

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

d. Jeffrey Keyser: trading record in brief

d. Jeffrey Keyser, listed as senior executive, appears in our data through filings on Lantern Pharma Inc. shares, published by SEC (Form 4). The record holds 2 filings, for trades running from 24 July 2024 to 12 May 2026.

No open-market sale appears; the market trades are 1 purchase worth €85k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant. So far in 2026, the count stands at 1 purchase and no sales.

On 14 May 2026 came the latest disclosure, an open-market purchase for €85k in Lantern Pharma Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.